Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder

Authors Walter Deberdt, Ilya Lipkovich, Alexandra N Heinloth, Lin Liu, Sara Kollack-Walker, et al

Published 8 August 2008 Volume 2008:4(4) Pages 713—720

DOI https://doi.org/10.2147/TCRM.S3153

Review by Single-blind

Peer reviewer comments 3

Walter Deberdt1, Ilya Lipkovich2, Alexandra N Heinloth3, Lin Liu2, Sara Kollack-Walker2, Sara E Edwards2, Vicki Poole Hoffmann2, Thomas A Hardy2

1Eli Lilly Benelux, Eli Lilly and Company, Brussels, Belgium; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 3i3Statprobe, Ingenix, Cary, NC, USA

Abstract: We examined the potential risks and benefits of switching from olanzapine to quetiapine in mentally stable, obese, or overweight patients with schizophrenia or schizoaffective disorder. Patients receiving olanzapine were randomized to continuing olanzapine treatment (N = 68; 7.5–20 mg/day) or switching to quetiapine (N = 65; 300–800 mg/day). Time to relapse was the primary study objective; secondary objectives included changes in weight, metabolic parameters, and psychiatric symptoms, and discontinuation rates. No significant difference in time to relapse was observed (p = 0.293), but significantly more patients remained on treatment in the olanzapine group compared with the quetiapine group (70.6% vs 43.1%; p = 0.002). Olanzapine-treated patients had significantly lower rates of study discontinuation for lack of efficacy and psychiatric adverse events (AEs) compared to quetiapine (2.94% vs 15.38%, p = 0.015). Significantly more patients in the olanzapine group experienced an increase in BMI ≥1 kg/m2. Olanzapine-treated patients experienced significantly greater increases in weight from Weeks 2 through 13. Switching patients with stable disease from olanzapine to quetiapine did not significantly shorten time to relapse, but produced more frequent study discontinuations due to lack of efficacy or psychiatric AEs with moderate but variable improvement in weight and no significant between-group differences in mean changes in metabolic laboratory parameters.

Keywords: antipsychotic switching, discontinuation, relapse, BMI, weight

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Histopathological and electron microscopic study for different grades of inferior oblique muscle overaction

Hamdi MM, El-Hawary GR, El-Hefnawy NG, Salman MI

Clinical Ophthalmology 2013, 7:917-921

Published Date: 21 May 2013

Respiratory management of the preterm newborn in the delivery room

Abdel-Hady H, Nasef N

Research and Reports in Neonatology 2012, 2:39-53

Published Date: 28 May 2012

Bowen’s disease – a review of newer treatment options

Thorsten Neubert, Percy Lehmann

Therapeutics and Clinical Risk Management 2008, 4:1085-1095

Published Date: 10 October 2008

Posaconazole in the management of refractory invasive fungal infections

Stefan Langner, Philipp B Staber, Peter Neumeister

Therapeutics and Clinical Risk Management 2008, 4:747-757

Published Date: 8 August 2008

New approaches to managing asthma: a US perspective

William E Berger

Therapeutics and Clinical Risk Management 2008, 4:363-379

Published Date: 11 April 2008

Treating refractory leukemias in childhood, role of clofarabine

Theresa M Harned, Paul S Gaynon

Therapeutics and Clinical Risk Management 2008, 4:327-336

Published Date: 11 April 2008

A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnon, Michael B Ward, Michael J Sorich

Therapeutics and Clinical Risk Management 2007, 3:751-759

Published Date: 15 November 2007